Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11466MR)

This product GTTS-WQ11466MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11466MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7941MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ1385MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ2365MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ8655MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ14879MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ11471MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ14792MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ10212MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW